Bhatta, L., Leivseth, L., Carslake, D., Langhammer, A., Mai, X-M., Chen, Y., ... Brumpton, B. (2019). Comparison of pre- and post-bronchodilator lung function as predictors of mortality: The HUNT Study. *Respirology*. https://doi.org/10.1111/resp.13648
Comparison of pre- and post-bronchodilator lung function as predictors of mortality: The HUNT Study

LAXMI BHATTA,1 LINDA LEIVSETH,2 DAVID CARSLAKE,3,4 ARNULF LANGHAMMER,5 XIANG-MEI MAI,1 YUE CHEN,6 ANNE H. HENRIKSEN7,8 AND BEN M. BRUMPTON3,8,9

1Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU Norwegian University of Science and Technology, Trondheim, Norway; 2Centre for Clinical Documentation and Evaluation (SKDE), Northern Norway Regional Health Authority, Tromsø, Norway; 3MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; 4Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; 5HUNT Research Centre, NTNU Norwegian University of Science and Technology, Levanger, Norway; 6School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada; 7Department of Circulation and Medical Imaging, NTNU Norwegian University of Science and Technology, Trondheim, Norway; 8Clinic of Thoracic and Occupational Medicine, St. Olavs Hospital, Trondheim, Norway; 9K.G. Jebsen Center for Genetic Epidemiology, NTNU Norwegian University of Science and Technology, Trondheim, Norway

ABSTRACT

Background and objective: Post-bronchodilator (BD) lung function is recommended for the diagnosis of chronic obstructive pulmonary disease (COPD). However, often only pre-BD lung function is used in clinical practice or epidemiological studies. We aimed to compare the discrimination ability of pre-BD and post-BD lung function to predict all-cause mortality.

Methods: Participants aged ≥40 years with airflow limitation (n = 2538) and COPD (n = 1262) in the second survey of the Nord-Trøndelag Health Study (HUNT2, 1995-1997) were followed up until 31 December 2015. Survival analysis and time-dependent area under the receiver operating characteristic curves (AUC) were used to compare the discrimination ability of pre-BD and post-BD lung function (percent-predicted forced expiratory volume in the first second (FEV1), FEV1 z-score, FEV1 quotient (FEV1Q), modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) categories or GOLD grades).

Results: Among 2538 participants, 1387 died. The AUC for pre-BD and post-BD ppFEV1, to predict mortality were 60.8 and 61.8 (P = 0.005), respectively, at 20 years' follow-up. The corresponding AUC for FEV1 z-score was 58.5 and 60.4 (P < 0.001), for FEV1Q were 68.7 and 70.1 (P = 0.002) and for modified GOLD categories were 62.3 and 64.5 (P < 0.001). Among participants with COPD, the AUC for pre-BD and post-BD ppFEV1 were 57.0 and 58.8 (P < 0.001), respectively. The corresponding AUC for FEV1 z-score were 53.1 and 55.8 (P < 0.001), for FEV1Q were 63.6 and 65.1 (P = 0.037) and for GOLD grades were 56.0 and 57.0 (P = 0.268).

Conclusion: Mortality was better predicted by post-BD than by pre-BD lung function; however, they differed only by a small margin. The discrimination ability using GOLD grades among COPD participants was similar.

Key words: area under the curve, mortality, post-bronchodilator, pre-bronchodilator, prediction.

INTRODUCTION

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), diagnosis and classification of chronic obstructive pulmonary disease (COPD) should be based on post-bronchodilator (BD) spirometric measurements. However, post-BD tests are time-consuming and not performed as frequently as recommended. Often, only pre-BD lung function is used in clinical practice or in epidemiological studies. Additionally, only a few studies have
compared mortality associated with both pre-BD and post-BD lung function.4,6 Mannino et al.,6 found similar mortality prediction for pre-BD and post-BD lung function in the general population. However, the area under the receiver operating characteristic curve (AUC) from logistic models was used to compare models, and this approach ignores important information about time-to-event concerning mortality. In contrast to Mannino et al.,6 Chen et al.4 and Fortis et al.,5 found post-BD to be better than pre-BD percent-predicted forced expiratory volume in the first second (ppFEV1) in predicting mortality. However, the study by Chen et al.4 included only a limited number of COPD patients (n = 300) from a pulmonary department and follow-up in both studies was limited to approximately 5 years.

We aimed to compare the discrimination ability of pre-BD and post-BD lung function to predict all-cause mortality in participants with airflow limitation or COPD selected from a large population-based study with over 20 years’ follow-up.

METHODS

Study population

The second survey of the Nord-Trøndelag Health Study (HUNT2, 1995–1997) invited the entire adult population (≥20 years old) of northern Trøndelag, Norway, to attend clinical examinations and answer questionnaires.7

The current study included participants aged ≥40 years in the HUNT2 Study (n = 44 384)7 with air-flow limitation (pre-BD FEV1/forced vital capacity (FVC) < 0.75 or FEV1 < 80% of predicted using the European Coal and Steel Community (ECSC) equations8) and acceptable pre-BD and post-BD spirometry manoeuvres (n = 2538) (Fig. S1, Appendix S1 in Supplementary Information).

Ethical approval was obtained from the Regional Committee for Medical Research Ethics (2015/1461/REK midt). All participants gave informed written consent.

Spirometry and lung function classification

Participants performed pre-BD and post-BD (30 min after inhalation of 1 mg terbutaline) spirometry according to the 1994 American Thoracic Society (ATS) guidelines with a heated pneumotachograph spirometer.9,10 Quality assurance of spirometric measurements is described in detail elsewhere.9,11 The Global Lung Function Initiative (GLI)-2012 reference equation was used to calculate ppFEV1, percent-predicted FVC (ppFVC) and to derive FEV1 z-scores based on lambda-mu-sigma (LMS) methods.9,12 In the LMS method, the median (Mu) represents how FEV1 changes with age, sex, height and ethnicity; the coefficient of variation (Sigma) models the spread of reference values; and the skewness (Lambda) models departure from normality.12,13 FEV1 was standardized by sex-specific lowest first percentile (0.5 L for men and 0.4 L for women) of FEV1, distribution to calculate the FEV1 quotient (FEV1Q).14 Pre-BD and post-BD lung function were classified into modified GOLD categories as follows: normal (FEV1/FVC ≥ 0.70 and ppFVC ≥ 80), preserved ratio impaired spirometry (FEV1/FVC ≥ 0.70 and ppFVC < 80), mild obstruction (FEV1/FVC < 0.70 and ppFEV1 ≥ 80), moderate obstruction (FEV1/ FVC < 0.70 and 80 > ppFEV1 ≥ 50), severe obstruction (FEV1/FVC < 0.70 and 50 > ppFEV1 ≥ 30) and very severe obstruction (FEV1/FVC < 0.70 and ppFEV1 < 30).1,15

Additionally, a COPD cohort (n = 1262) was defined as having persistent airflow limitation (pre-BD and post-BD FEV1/FVC < 0.70) concurrent with respiratory symptoms or self-reported doctor-diagnosed COPD.1 Respiratory symptoms included daily cough, wheezing and dyspnoea. GOLD grades were defined as GOLD1 (ppFEV1 ≥ 80), GOLD2 (80 > ppFEV1 ≥ 50), GOLD3 (50 > ppFEV1 ≥ 30) and GOLD4 (ppFEV1 < 30) in the COPD cohort.1

Clinical examination and questionnaires

Information on age (years), sex, body mass index (BMI, kg/m²), smoking status, smoking pack-years, physical activity, education, diabetes ever, asthma ever, cardiovascular disease, systolic blood pressure (mm Hg) and non-fasting total serum cholesterol (mmol/L) was ascertained from clinical examination and questionnaires.

Age was recorded to one decimal place. Height and weight were measured with light clothing and without shoes, and rounded to the nearest centimetre or half kilogram, respectively.16,17 Cardiovascular disease included self-reported angina pectoris, myocardial infarction and stroke. Systolic blood pressure was measured three times and the mean of the last two measurements was used.17

Follow-up and outcome

HUNT2 participants (1995–1997) were followed up until death, emigration (n = 6) or 31 December 2015. The Norwegian Cause of Death Registry provided information on date of death.

Statistical analysis

Mortality rates per 1000 person-years with 95% CI were calculated. We used log-rank test of Kaplan–Meier estimates for mortality. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% CI for the associations of pre-BD and post-BD lung function with mortality. We presented crude HR (Model 1) and adjusted HR (Model 2). Model 2 accounted for age (as a continuous variable), sex (women and men), smoking (never, former (<10, 10–19 and ≥20 pack-years), current (<10, 10–19 and ≥20 pack-years) and unknown), BMI (<25.0, 25.0–29.9, ≥30.0 and unknown) and education (<10, ≥10 years and unknown). In supplementary analyses, we additionally adjusted for physical activity (none, light exercise, hard exercise and unknown), cardiovascular diseases (no, yes and unknown), asthma ever (no, yes and unknown), diabetes ever (no, yes and unknown), systolic blood pressure (sex-specific
Table 1  Characteristics of participants aged ≥40 years with airflow limitation stratified by modified GOLD categories in the HUNT2 Study (1995–1997)

| Characteristic                  | Pre-BD†          | Post-BD†         |
|--------------------------------|------------------|------------------|
|                                | Normal (n = 709) | PRISm (n = 177)  |
|                                | Mild obstructive (n = 501) | Moderate obstructive (n = 858) | Severe obstructive (n = 248) | Very severe obstructive (n = 45) | Normal (n = 946) | PRISm (n = 167)  |
| Participants (%)               | 27.9             | 7.0              | 19.7             | 33.8             | 9.8             | 1.8             | 37.3             | 6.6             | 18.7             | 30.0             | 6.7             | 0.7             |
| Age (years) (mean ± SD)        | 58.4 ± 11.9      | 61.8 ± 11.5      | 62.8 ± 11.8      | 64.5 ± 10.9      | 67.9 ± 10.2     | 65.4 ± 9.2      | 58.2 ± 11.8      | 62.2 ± 11.8      | 64.9 ± 11.3      | 65.5 ± 10.4      | 68.0 ± 9.5      | 64.7 ± 10.4      |
| BMI (mean ± SD)                | 26.9 ± 4.0       | 29.5 ± 6.4       | 26.8 ± 3.8       | 27.0 ± 4.6       | 25.4 ± 4.5      | 23.6 ± 3.5      | 27.2 ± 4.2       | 29.6 ± 6.3       | 26.7 ± 3.9       | 26.7 ± 4.6       | 24.6 ± 4.0       | 23.2 ± 2.6       |
| Smoking pack-years (mean ± SD) | 17.8 ± 12.3      | 20.9 ± 14.5      | 20.8 ± 13.5      | 24.6 ± 14.9      | 25.2 ± 16.3     | 33.2 ± 19.0     | 18.1 ± 12.2      | 20.8 ± 14.2      | 22.6 ± 14.6      | 24.9 ± 15.1      | 27.5 ± 16.5      | 28.9 ± 24.5      |
| Current smoker (%)             | 34.3             | 35.6             | 37.7             | 49.1             | 46.6             | 38.6             | 33.8             | 35.6             | 42.8             | 50.3             | 46.3             | 26.3             |
| Physically inactive (%)        | 7.1              | 11.5             | 8.0              | 11.1             | 10.7             | 13.5             | 7.0              | 11.9             | 10.4             | 10.9             | 9.7              | 18.8             |
| Education ≥10 years (%)        | 51.9             | 40.0             | 47.0             | 36.6             | 29.8             | 26.3             | 52.1             | 37.4             | 40.8             | 35.5             | 28.3             | 31.3             |
| Cardiovascular disease (%)     | 13.3             | 19.8             | 15.8             | 21.5             | 19.8             | 13.9             | 12.6             | 19.2             | 19.0             | 21.8             | 21.3             | 22.2             |
| Asthma ever (%)                | 45.8             | 54.8             | 47.7             | 59.0             | 77.4             | 93.3             | 47.6             | 50.9             | 52.1             | 61.4             | 78.2             | 94.7             |
| Diabetes ever (%)              | 4.2              | 10.9             | 4.8              | 4.9              | 3.6              | 6.8              | 3.6              | 11.0             | 5.3              | 5.3              | 4.1              | 5.3              |
| SBP (mean ± SD)                | 141.1 ± 20.7     | 146.3 ± 23.3     | 145.5 ± 23.5     | 146.8 ± 22.2     | 149.9 ± 24.4     | 143.5 ± 19.7     | 141.2 ± 21.2     | 145.8 ± 24.1     | 147.1 ± 23.2     | 147.9 ± 22.1     | 149.7 ± 24.8     | 136.9 ± 19.8     |
| Cholesterol (mean ± SD)        | 6.2 ± 1.2        | 6.4 ± 1.2        | 6.2 ± 1.2        | 6.3 ± 1.2        | 6.3 ± 1.2        | 6.3 ± 1.0        | 6.2 ± 1.2        | 6.4 ± 1.3        | 6.3 ± 1.2        | 6.3 ± 1.2        | 6.2 ± 1.2        | 6.3 ± 1.0        |

†Normal: FEV1/FVC ≥ 0.70 and ppFVC ≥ 80; PRISm: FEV1/FVC ≥ 0.70 and ppFVC < 80; mild obstructive: FEV1/FVC < 0.70 and ppFEV1 ≥ 80; moderate obstructive: FEV1/FVC < 0.70 and 80 > ppFEV1 ≥ 50; severe obstructive, FEV1/FVC < 0.70 and 50 > ppFEV1 ≥ 30; very severe obstructive: FEV1/FVC < 0.70 and ppFEV1 < 30.

BD, bronchodilator; BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HUNT2, the second survey of the Nord-Trøndelag Health Study (1995–1997); ppFEV1, percent-predicted FEV1; ppFVC, percent-predicted FVC; PRISm, preserved ratio impaired spirometry.
quartiles and unknown) and cholesterol (sex-specific quartiles and unknown) (Model 3).

Multicollinearity was tested where the variance inflation factor (VIF) was less than 1.5 in all models. Proportional hazard assumptions were evaluated using log-log survival curves and Schoenfeld residual test. As a measure of goodness of fit, we estimated the Akaike information criteria (AIC) and performed Gronnesby and Borgan tests for each model (Table S1 in Supplementary Information).

We calculated time-dependent AUC to compare the discrimination ability of pre-BD and post-BD lung function to predict mortality. The incident/dynamic (I/D) AUC models account for cumulative cases at time t and dynamic controls, which means it characterizes the cumulative number of deaths up to time t. The incidence/dynamic controls, which means it characterizes the time-varying performance without selecting a particular timeframe over which cases accrue, whereas cumulative/dynamic (C/D) AUC models account for cumulative cases at time t and dynamic controls.

We compared the AUC for crude models because the clinical decision usually does not explicitly take other factors into account. Additionally, as a global measure of informativeness, we calculated concordance index (C-index). A general bootstrap algorithm (gBA) was applied to calculate 95% CI for I/D AUC and C-index.

We performed all the analyses both among participants with airflow limitation and among participants with COPD. Statistical analysis was performed using R 3.5.0 (http://www.r-project.org) and Stata 15.1 (StataCorp., College Station, TX, USA).

### RESULTS

In the cohort of participants with airflow limitation, the median and maximum follow-up times were 17.8 and 20.4 years, respectively. Based on pre-BD lung function at baseline, 27.9% had normal lung function and 1.8% had very severe obstruction. Corresponding proportions for post-BD lung function were 37.3% and 0.7%, respectively (Table 1). The distribution of participants between pre-BD and post-BD modified GOLD categories is presented in Table S2 in Supplementary Information.

A trend for increasing age, smoking pack-years, physical activity and mortality rates, and decreasing education and BMI with worsening modified GOLD categories was observed for both pre-BD and post-BD lung function (Table 1, Table S3 in Supplementary Information). We observed a similar increasing trend of mortality in unadjusted cumulative incidence curves (Fig. S2 in Supplementary Information).

A 10% reduction in ppFEV1 and 1-unit reduction in FEV1 z-score and FEV1/Q were associated with 19%, 36% and 33% increased risk of death, respectively, using pre-BD lung function. Similarly, worsening modified GOLD categories were associated with increased risk of death. Results were similar for post-BD lung function (Table 2, Model 2), in Model 3 (Table S4 in Supplementary Information) and among participants with COPD (Table S5 in Supplementary information).

The I/D AUC (95% CI) for pre-BD and post-BD ppFEV1 were 60.8 (59.3–62.2) and 61.8 (60.2–63.4), respectively, for mortality at 20 years’ follow-up.

### Table 2  HR for pre-BD and post-BD lung function among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997)

| Lung function | Pre-BD | Post-BD |
|---------------|--------|---------|
|               | Model 1 HR (95% CI) | Model 2 HR (95% CI) | Model 1 HR (95% CI) | Model 2 HR (95% CI) |
| ppFEV1<sup>1</sup> | 1.28 (1.24–1.31) | 1.19 (1.16–1.22) | 1.31 (1.27–1.34) | 1.22 (1.19–1.25) |
| FEV1 z-score<sup>2</sup> | 1.31 (1.26–1.37) | 1.36 (1.30–1.42) | 1.40 (1.34–1.45) | 1.41 (1.35–1.48) |
| FEV1/Q<sup>3</sup> | 1.67 (1.61–1.73) | 1.33 (1.27–1.39) | 1.72 (1.66–1.78) | 1.38 (1.32–1.44) |
| Modified GOLD categories<sup>4</sup> |  |  |  |  |
| Normal | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| PRISM | 2.33 (1.85–2.94) | 1.79 (1.41–2.26) | 2.59 (2.08–3.24) | 1.95 (1.56–2.45) |
| Mild obstructive | 1.77 (1.47–2.12) | 1.17 (0.98–1.41) | 2.12 (1.80–2.50) | 1.16 (0.98–1.37) |
| Moderate obstructive | 2.78 (2.38–3.25) | 1.78 (1.52–2.08) | 3.20 (2.78–3.69) | 1.86 (1.60–2.15) |
| Severe obstructive | 5.23 (4.32–6.33) | 2.77 (2.27–3.37) | 6.59 (5.41–8.02) | 3.44 (2.80–4.23) |
| Very severe obstructive | 7.00 (5.02–9.75) | 5.03 (3.57–7.08) | 6.00 (3.73–9.67) | 4.68 (2.89–7.59) |

<sup>1</sup>Normal: FEV1/FVC ≥ 0.70 and ppFEV1 ≥ 80; PRISM: FEV1/FVC ≥ 0.70 and ppFVC < 80; mild obstructive: FEV1/FVC < 0.70 and ppFEV1 ≥ 80; moderate obstructive: FEV1/FVC < 0.70 and 80 > ppFEV1 ≥ 50; severe obstructive: FEV1/FVC < 0.70 and 50 > ppFEV1 ≥ 30; very severe obstructive: FEV1/FVC < 0.70 and ppFEV1 < 30.

<sup>2</sup>FEV1 standardized by sex-specific lowest first percentile (0.5 L for men and 0.4 L for women) of FEV1 distribution. HR were for a 1-unit reduction in FEV1/Q.

<sup>3</sup>FEV1 z-score based on GLI-2012 equation. HR were for a 1-unit reduction in FEV1 z-score.

<sup>4</sup>ppFEV1 based on GLI-2012 equation. HR were for a 10% reduction in ppFEV1.

<sup>5</sup>Crude model.

<sup>6</sup>Adjusted for age, sex, smoking, body mass index and education.

BD, bronchodilator; FEV1, forced expiratory volume in the first second; FEV1/Q, FEV1 quotient; FVC, forced vital capacity; GLI, Global Lung Function Initiative; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; HUNT2, the second survey of the Nord-Trøndelag Health Study (1995–1997); ppFEV1, percent-predicted FEV1; ppFVC, percent-predicted FVC; PRISm, preserved ratio impaired spirometry.
(P = 0.005) (Table 3, Fig. 1, Fig. S3 in Supplementary Information). A similar pattern was observed over time (Fig. 1). Corresponding estimates for FEV₁ z-score were 58.5 (57.0–59.9) and 60.4 (58.8–62.0) (P < 0.001), for FEV₁Q were 68.7 (66.8–70.5) and 70.1 (68.1–72.1) (P = 0.002) and for modified GOLD categories were 62.3 (60.6–63.8) and 64.5 (62.9–66.1) (P < 0.001) (Table 3, Fig. 1, Fig. S3 in Supplementary Information).

Among participants with COPD, the I/D AUC (95% CI) for pre-BD and post-BD ppFEV₁ were 57.0 (55.1–58.8) and 58.8 (56.7–60.8), respectively, for predicting mortality at 20 years’ follow-up (P < 0.001) and results were similar over time (Fig. 2, Table S6 in Supplementary Information). Corresponding estimates for FEV₁ z-score were 53.1 (95% CI: 51.5–54.8) and 55.8 (95% CI: 53.9–57.7) (P < 0.001), for FEV₁Q were 63.6 (95% CI: 60.9–65.9) and 65.1 (95% CI: 62.0–67.9) (P = 0.037) and for GOLD grades were 56.0 (95% CI: 53.9–57.9) and 57.0 (95% CI: 54.6–59.2) (P = 0.268) (Fig. 2, Table S6 in Supplementary Information).

The results from C-index and C/D AUC (Tables S6, S7, Figs S4, S5 in Supplementary Information) were generally in agreement with I/D AUC.

### DISCUSSION

In this large population-based study of participants with airflow limitation, mortality was slightly better predicted by post-BD than by pre-BD lung function whether using ppFEV₁, FEV₁ z-score, FEV₁Q or modified GOLD categories. Among participants with COPD, the discrimination ability of post-BD was slightly higher than pre-BD to predict mortality using ppFEV₁, FEV₁ z-score or FEV₁Q but the discrimination ability using GOLD grades was similar.

Similar to our study, other studies have found that decreased ppFEV₁, FEV₁ z-score or FEV₁Q are associated with an increased risk of death. Furthermore, a study by Mannino et al. found that the risk of death increased with worsening GOLD-defined airflow limitation, where participants with severe or very severe obstruction were associated with 4.5 times higher risk of dying compared to participants with normal lung function. HR were slightly higher than in our study, likely due to the exclusion of participants with respiratory symptoms from their reference population.

The discrimination ability of pre-BD and post-BD lung function to predict mortality was generally poor except for FEV₁Q which had fair discrimination ability. Nevertheless, we found that mortality was better predicted by post-BD than by pre-BD lung function at 20 years’ follow-up, and this was consistent over time in models using ppFEV₁, FEV₁ z-score, FEV₁Q or modified GOLD categories. There are no previous studies directly comparing the discrimination ability of pre-BD and post-BD lung function as a predictive marker of mortality when other predictors are not taken into consideration and no studies have included measurements of FEV₁ z-score and FEV₁Q. However, in a study by Fortis et al. that followed up 8221 adults for approximately 6.5 years, post-BD was a stronger predictor for mortality than pre-BD lung function in models adjusted with covariates. We found similar results in our study at 6.5 years’ follow-up for mortality in both crude and adjusted models (P < 0.001 for both, results not shown). Additionally, one study investigated 5887 adults from the general population participating in NHANES and compared the predictive ability of pre-BD and post-BD lung function for mortality after 20 years. In this study, Mannino et al. found that pre-BD and post-BD lung function similarly predicted mortality where the AUC for pre-BD and post-BD ppFEV₁ were 69.2 and 69.4, respectively, and for pre-BD and post-BD modified GOLD categories the AUC were 69.2 and 69.6, respectively. Compared to our study, this study included other predictors of mortality and AUC were calculated from logistic regression models, which do not take account of time-to-event. However, at 20 years’ follow-up, when we included other predictors of mortality in our models the results were similar to Mannino et al. (Table S8 in Supplementary Information). This suggests that when other factors are considered, including post-BD lung function in models might not be more informative than pre-BD lung function at predicting long-term mortality.

Among participants with COPD, mortality was better predicted by post-BD ppFEV₁, FEV₁ z-score and FEV₁Q.
than by pre-BD ppFEV₁, FEV₁ z-score and FEV₁Q, respectively, at 20 years’ follow-up. Over time, the difference was constant for pre-BD and post-BD ppFEV₁, post-BD FEV₁ z-score or post-BD FEV₁Q. However, for GOLD grades, the discrimination ability was similar at 20 years’ follow-up and this pattern was constant over time. To our knowledge, no other studies have compared pre-BD and post-BD lung function using FEV₁ z-score or FEV₁Q, and only one study has compared pre-BD- and post-BD-defined GOLD grades in predicting mortality among participants with COPD. In contrast to our study, Chen et al. found that mortality was better predicted by post-BD than by pre-BD lung function after 51 months (approximately 4 years) of follow-up among 300 COPD patients from a pulmonary department. The discrimination ability for mortality was compared between pre-BD and post-BD GOLD grades using log-rank tests (Kaplan–Meier estimates) where respective models had \( P = 0.131 \) and \( P = 0.009 \). The disagreement between Chen et al. and our study might be due to methodological differences between studies (log-rank method vs time-dependent AUC used in our study).

BD dilate bronchi and bronchioles to reverse the airflow limitation. In COPD, airflow limitation is variable and primarily irreversible where use of BD features small reversible components. GOLD guidelines recommend post-BD spirometry for the classification of COPD. It is also reported that lung function reference values for post-BD differ from pre-BD spirometry in the general population. However, often, only pre-BD lung function is used in clinical practice or in epidemiological studies. Therefore, to compare which measure best predicts mortality is an important question for respiratory medicine. In our study, we observed that mortality was better predicted by post-BD than by pre-BD lung function among participants with airflow limitation, by a margin of approximately 2%. This potential gain in discrimination ability, if replicated in other studies, should be evaluated against the cost and clinical significance of such measurements in this subgroup of individuals. Among participants with COPD, mortality did not seem to be better predicted by post-BD-defined GOLD grades than by pre-BD. This study could have clinical implications as to how procedures might be prioritized in different subgroups.

This study had several strengths. It is the first study to investigate the discrimination ability of pre-BD and post-BD lung function over a 20-year period to predict mortality using FEV₁ z-score and FEV₁Q. The study is based on the HUNT2 Lung Study which had a reasonably high level of participation (76.0% of invited Lung Study population), which limits potential selection bias. We had complete information on mortality and there

![Figure 1](image-url)
was no loss to follow-up other than very few emigrations (6 out of 2538 participants). To reduce measurement error, quality assurance of spirometry curves was performed.\textsuperscript{9,11}

This study however had certain limitations. Participants with airflow limitation from the HUNT2 Lung Study were included; therefore, these findings may not necessarily apply to the general population. Additionally, there was missing information on some covariates; therefore, to avoid sample loss in adjusted models, a missing indicator variable (missing information as unknown category) was used which might bias the association between lung function and mortality. The HUNT population is homogeneous; therefore, generalizability of findings outside a non-Caucasian population might be limited.

In summary, we found that mortality was better predicted by post-BD than by pre-BD lung function; however, they differed only by a small margin. The discrimination ability using GOLD grades among COPD participants was similar. The clinical significance of the findings in daily handling of patients should be studied further.

**Acknowledgements:** The Nord-Trøndelag Health (HUNT) Study is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Science, Norwegian University of Science and Technology NTNU), Nord-Trøndelag County Council and the Norwegian Institute of Public Health. The HUNT2 Lung Study was partly funded through a non-demanding grant from AstraZeneca Norway.

**Disclosure statement:** This study was funded by ExtraStiftelsen Helse og Rehabilitering and Landsforeningen for hjerte-og-lungesyke (the Norwegian Extra Foundation for Health and Rehabilitation and the Norwegian Heart and Lung Patient Organization) (project number 2016/FO79031) and the Liaison Committee of the Central Norway Regional Health Authority – NTNU (Norwegian University of Science and Technology). B.M.B. works in a research unit funded by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU; The Liaison Committee for Education, Research and Innovation in Central Norway; the Joint Research Committee between St Olavs Hospital and the Faculty of Medicine and Health Sciences, NTNU; and the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council and the University of Bristol (MC_UU_12013/1). D.C. works in a unit funded by the UK Medical Research Council (MC_UU_00011/1) and the University of Bristol.

**Author contributions:** Conceptualization: L.B., L.L., A.L., B.M.B. Data curation: A.L. Formal analysis: L.B. Funding acquisition: B.M.B., L.L. Investigation: L.B., B.M.B. Methodology: L.B., B.M.B. Project administration: B.M.B., L.L., D.C., A.L., X.-M.M., Y.C., A.H.H. Validation: L.B.,

---

**Figure 2** Incident/dynamic time-dependent area under the receiver operating characteristic curve (AUC) for pre-bronchodilator (BD) (-----) and post-BD (----) (A) percent-predicted forced expiratory volume in the first second (FEV\textsubscript{1}), (B) FEV\textsubscript{1} z-score, (C) FEV\textsubscript{1} quotient (FEV\textsubscript{1}Q) and (D) Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades for all-cause mortality change over follow-up time (years) among participants aged ≥40 years with chronic obstructive pulmonary disease (COPD) in the second survey of the Nord-Trøndelag Health Study (HUNT2, 1995–1997).
B.M.B. Visualization; L.B. Writing—original draft; L.B. Writing—review and editing; L.B., LL., D.C., A.L., X.-M.M., Y.C., A.H.H., B.M.B.

Abbreviations: AUC, area under the receiver operating characteristic curve; BD, bronchodilator; C/D, cumulative/dynamic; C-index, concordance index; FEV₁, forced expiratory volume in the first second; FEV₁/FVC, quotient; FVC, forced vital capacity; GLI, Global Lung Function Initiative; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio; HUNT2, the second survey of the Nord-Trøndelag Health Study (1995–1997); I/D, incident/dynamic; LMS, lambda-mu-sigma; ppFEV₁, percent-predicted FEV₁; ppFVC, percent-predicted FVC; PRISm, preserved ratio impaired spirometry.

REFERENCES
1 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017. [Accessed 1 August 2017.] Available from URL: http://goldcopd.org/
2 Fromer L. Diagnosing and treating COPD: understanding the challenges and finding solutions. Int. J. Gen. Med. 2011; 4: 729–39.
3 Yawn BP, Wollan PC. Knowledge and attitudes of family physicians coming to COPD continuing medical education. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3: 311–8.
4 Chen CZ, Ou CY, Wang WL, Lee CH, Lin CC, Chang HY, Hsiue TR. Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity. COPD 2012; 9: 276–80.
5 Fortis S, Eberlein M, Georgopoulos D, Comellas AP. Predictive value of prebronchodilator and post-bronchodilator spirometry for COPD features and outcomes. BMJ Open Respir. Res. 2017; 4: e000213.
6 Mannino DM, Diaz-Guzman E, Buist S. Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study. Respir. Res. 2011; 12: 136.
7 Krookstad S, Langhammer A, Hveem K, Holmen TL, Midtbjell K, Stene TR, Bratberg H, Heggeland I, Holmen J. Cohort profile: the HUNT Study, Norway. Int. J. Epidemiol. 2013; 42: 966–77.
8 Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. Suppl. 1993; 16: 5–40.
9 Langhammer A, Johannessen A, Holmen TL, Melbye H, Stanoevich S, Lund MB, Melsom MN, Bakke P, Quanjer PH. Global Lung Function Initiative 2012 reference equations for spirometry in the Norwegian population. Eur. Respir. J. 2016; 48: 1602–11.
10 Standardization of Spirometry, 1994 Update. American Thoracic Society. Am. J. Respir. Crit. Care Med. 1995; 152: 1107–36.
11 Hankinson JL, Eschenbacher B, Townsend M, Stocks J, Quanjer PH. Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test. Eur. Respir. J. 2015; 45: 1283–92.
12 Quanjer PH, Stanoevich S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MSM, Zheng J et al.; The ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95 year age range: the Global Lung Function 2012 equations: report of the Global Lung Function Initiative (GLI). ERS Task Force to establish improved lung function reference values. Eur. Respir. J. 2012; 40: 1324–43.
13 Stanoevich S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, Rosenthal M, Corey M, Lebecque P, Cole TJ. Reference ranges for spirometry across all ages: a new approach. Am. J. Respir. Crit. Care Med. 2008; 177: 253–60.
14 Miller MR, Pedersen OF. New concepts for expressing forced expiratory volume in 1 s arising from survival analysis. Eur. Respir. J. 2010; 35: 873–82.
15 Wan ES, Castaldi PJ, Cho MH, Hokanson JE, Regan EA, Make BJ, Beatty TH, Han MK, Curtis JL, Curran-Everett D et al.; COPDGene Investigators. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir. Res. 2014; 15: 89.
16 Bhatia L, Leivseth L, Mai X-M, Chen Y, Henriksen AH, Langhammer A, Brumpton BM. Prevalence and trend of COPD from 1995–1997 to 2006–2008: the HUNT study, Norway. Respir. Med. 2018; 130: 50–6.
17 Holmen J, Midtbjell K, Krüger Ø, Langhammer A, Holmen TL, Bratberg GH, Vatten L, Lund-Larsen PG. The Nord-Trøndelag Health Study 1995–97 (HUNT 2): objectives, contents, methods and participation. Nor. Epidemiol. 2003; 13: 19–32.
18 Belsley DA, Kuh E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York, Wiley, 1980.
19 Briët RM. A caution regarding rules of thumb for variance inflation factors. Qual. Quant. 2007; 41: 673–90.
20 Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–26.
21 Bozdogan H. Model selection and Akaike’s information criterion (AIC): the general theory and its analytical extensions. Psychometrika 1987; 52: 345–70.
22 May S, Hosmer DW. A cautionary note on the use of the Grennesby and Borgan goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal. 2004; 10: 283–91.
23 Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat. Med. 2013; 32: 5381–97.
24 Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med. Res. Methodol. 2017; 17: 53.
25 Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61: 92–105.
26 Saha P, Heagerty PJ. Time-dependent predictive accuracy in the presence of competing risks. Biometrics 2010; 66: 999–1011.
27 Bansal A, Heagerty PJ. A tutorial on evaluating the time-varying discrimination accuracy of survival models used in dynamic decision making. Med. Decis. Making 2018; 38: 904–16.
28 Soriano JB, Lamprecht B, Ramirez AS, Martinez-Cambor P, Kaiser B, Aafsgeme I, Almagro P, Casanova C, Esteban C, Soler-Cataluna JJ et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir. Med. 2015; 3: 143–50.
29 Martinez-Cambor P, Corral N. A general bootstrap algorithm for hypothesis testing. J. Stat. Plan. Inference 2012; 142: 589–600.
30 Gupta RP, Strachan DP. Ventilatory function as a predictor of mortality in lifelong non-smokers: evidence from large British cohort studies. BMJ Open 2017; 7: e015381.
31 Tejero E, Prats E, Casitas R, Galera R, Pardo P, Gavilan A, Martinez-Ceron E, Cataluna JJ et al. Mortality and airflow obstruction in lifelong non-smokers: evidence from large British cohort studies. BMJ Open 2017; 7: e015381.
32 Stanojevic S, Coates AL, Pan H, Holmen TL, Bratberg GH, Vatten L, Lund-Larsen PG. The Nord-Trøndelag Health Study 1995–97 (HUNT 2): objectives, contents, methods and participation. Nor. Epidemiol. 2003; 13: 19–32.
33 Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J. Thorac. Oncol. 2010; 5: 1315–6.
34 Sterk PJ. Let’s not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV₁. Eur. Respir. J. 2004; 23: 497–8.
35 Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A. Post-bronchodilator spirometry reference values in adults and implications for disease management. Am. J. Respir. Crit. Care Med. 2006; 173: 1316–25.
Supplementary Information

Additional supplementary information can be accessed via the html version of this article at the publisher’s website.

Appendix S1 Study population.
Figure S1 Flow chart: pre-bronchodilator (BD) and post-BD spirometry among people aged ≥40 years in the HUNT2 Study.
Figure S2 Cumulative incidence curves of all-cause mortality for pre-bronchodilator (BD) and post-BD modified GOLD categories among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Figure S3 Incident/dynamic time-dependent ROC curve (Model 1) for pre-bronchodilator (BD) and post-BD (A) percent-predicted forced expiratory volume in the first second (FEV₁), (B) FEV₁ z-score, (C) FEV₁Q and (D) modified GOLD categories for all-cause mortality at 20 years’ follow-up time among participants aged ≥40 years with airflow limitation in the HUNT2 study (1995–1997).
Figure S4 Cumulative/dynamic time-dependent AUC (Model 1) for pre-bronchodilator (BD) and post-BD (A) percent-predicted forced expiratory volume in the first second (FEV₁), (B) FEV₁ z-score, (C) FEV₁Q and (D) modified GOLD categories for all-cause mortality change over follow-up time (years) among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Figure S5 Cumulative/dynamic time-dependent AUC (Model 1) for pre-bronchodilator (BD) and post-BD (A) percent-predicted forced expiratory volume in the first second (FEV₁), (B) FEV₁ z-score, (C) FEV₁Q and (D) GOLD grades for all-cause mortality change over follow-up time (years) among participants aged ≥40 years with COPD in the HUNT2 Study (1995–1997).
Table S1 Akaike information criteria and Gronnesby and Borgan goodness-of-fit test (χ²) of pre-bronchodilator (BD) and post-BD lung function among participants aged ≥40 years with airflow limitation or COPD in the HUNT2 Study (1995–1997).
Table S2 Pre-bronchodilator (BD) and post-BD modified GOLD categories of participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Table S3 Mortality rate for pre-bronchodilator (BD) and post-BD modified GOLD categories among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Table S4 Hazard ratios for pre-bronchodilator (BD) and post-BD lung function among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Table S5 Hazard ratios for pre-bronchodilator (BD) and post-BD lung function among participants aged ≥40 years with COPD in the HUNT2 Study (1995–1997).
Table S6 Incident/dynamic time-dependent area under the receiver operating characteristic curve (AUC), C-index and cumulative/dynamic time-dependent AUC for pre-bronchodilator (BD) and post-BD lung function at 20 years of follow-up among participants aged ≥40 years with COPD in the HUNT2 Study (1995–1997).
Table S7 C-index and cumulative/dynamic time-dependent AUC for pre-bronchodilator (BD) and post-BD lung function at 20 years of follow-up among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).
Table S8 Incident/dynamic time-dependent AUC for pre-bronchodilator (BD) and post-BD lung function at 20 years of follow-up among participants aged ≥40 years with airflow limitation in the HUNT2 Study (1995–1997).